Cytokinetics
CYTK
157 hedge funds and large institutions have $1.36B invested in Cytokinetics in 2020 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 61 increasing their positions, 50 reducing their positions, and 15 closing their positions.
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
57% more capital inflows, than outflows
Capital inflows: $194M | Capital outflows: $123M
22% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 50
8% more funds holding
Funds holding: 145 → 157 (+12)
3.65% more ownership
Funds ownership: 93.71% → 97.36% (+3.7%)
33% less call options, than puts
Call options by funds: $5.33M | Put options by funds: $7.93M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$56.5M |
| 2 |
Farallon Capital Management
San Francisco,
California
|
+$16.4M |
| 3 |
Great Point Partners
Greenwich,
Connecticut
|
+$16.1M |
| 4 |
Logos Global Management
San Francisco,
California
|
+$11.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
-$46.4M |
| 2 |
Foresite Capital Management IV
Larkspur,
California
|
-$10.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.11M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.68M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$8.43M |
CYTK Hedge Fund Activity: Q2 2020 in Review
157 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2020, worth a combined $1.36B — up 108% from $657M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CYTK positions and 15 closed out — a net gain of 13 holders — while 61 added to existing stakes and 50 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $56.5M. The largest seller was BVF Inc, exiting entirely with an estimated $46.4M sold.
- 157 institutional investors held Cytokinetics (CYTK) as of Q2 2020, up from 145 in Q1 2020.
- Funds reported $1.36B of Cytokinetics stock for Q2 2020, up 108% quarter-over-quarter.
- 28 funds opened new Cytokinetics positions in Q2 2020 and 15 closed out, a net change of +13 holders.
- The largest Cytokinetics buyer in Q2 2020 was Wellington Management Group, an estimated $56.5M added.
- The largest Cytokinetics seller in Q2 2020 was BVF Inc, an estimated $46.4M sold.
Based on aggregated 13F filings for Q2 2020.